In 2012, Mike McFadden’s business managed a merger between then American-based Jazz Pharmaceuticals and the Irish drugmaker Azur Pharma. The transaction led Jazz Pharmaceuticals overseas to Ireland where it could avoid paying U.S. taxes, a practice commonly referred to as an “inversion.”
